Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Meng, Ran ^a,b   Tang, Heng Yuan ^a   Westfall, Jennifer ^a   London, David ^a   Cao, James H ^a   Mousa, Shaker A ^b,e   Luidens, Mary ^a,c   Hercbergs, Aleck ^d   Davis, Faith B ^a   Davis, Paul J ^a,b,c   Lin, Hung Yun ^a,b  

^a Ordway Signal Transduction   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CYCLINE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HORMONE RECEPTOR BLOCKING AGENT; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TETRAIODOTHYROACETIC ACID; THYMIDINE; THYROID HORMONE; THYROXINE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; HORMONE ACTION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION; CELL NUCLEUS; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; THYROID HORMONES; THYROXINE;

EID: 81555212294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027547     Document Type: Article

References (37)

1. Cheng SY, Leonard JL, Davis PJ, (2010) Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139-170.
2. Yen PM, (2006) Thyroid hormones and 3,5-diiodothyropropionic acid: new keys for new locks. Endocrinology 147: 1598-1601.
3. Francavilla A, Carr BI, Azzarone A, Polimeno L, Wang Z, et al. (1994) Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. Hepatology 20: 1237-1241.
4. Malik R, Mellor N, Selden C, Hodgson H, (2003) Triiodothyronine enhances the regenerative capacity of the liver following partial hepatectomy. Hepatology 37: 79-86.
5. Di Fulvio M, Coleoni AH, Pellizas CG, Masini-Repiso AM, (2000) Tri-iodothyronine induces proliferation in cultured bovine thyroid cells: evidence for the involvement of epidermal growth factor-associated tyrosine kinase activity. J Endocrinol 166: 173-182.
6. Chattergoon NN, Giraud GD, Thornburg KL, (2007) Thyroid hormone inhibits proliferation of fetal cardiac myocytes in vitro. J Endocrinol 192: R1-8.
7. Tang HY, Lin HY, Zhang S, Davis FB, Davis PJ, (2004) Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145: 3265-3272.
8. Davis FB, Tang HY, Shih A, Keating T, Lansing L, et al. (2006) Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66: 7270-7275.
9. Lin HY, Tang HY, Shih A, Keating T, Cao G, et al. (2007) Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72: 180-187.
10. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, et al. (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500-1506.
11. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, et al. (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864-2871.
12. Desgrosellier JS, Cheresh DA, (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
13. Belmadani S, Zerfaoui M, Boulares HA, Palen DI, Matrougui K, (2008) Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol 295: H69-76.
14. Cai W, Chen X, (2006) Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6: 407-428.
15. Byzova TV, Kim W, Midura RJ, Plow EF, (2000) Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 254: 299-308.
16. Cody V, Davis PJ, Davis FB, (2007) Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin. Steroids 72: 165-170.
17. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, et al. (2009) L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980-991.
18. Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, et al. (2009) Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 297: E1238-1246.
19. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, et al. (2008) Metabolic effects of thyroid hormone derivatives. Thyroid 18: 239-253.
20. Shih A, Lin HY, Davis FB, Davis PJ, (2001) Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 40: 2870-2878.
21. Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ, (2009) Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure. Clin Cancer Res 15: 3672-3679.
22. Lin C, Crawford DR, Lin S, Hwang J, Sebuyira A, et al. (2011) Inducible COX-2-dependent apoptosis in human ovarian cancer cells. Carcinogenesis 32: 19-26.
23. Lin HY, Tang HY, Lin C, Sun M, Davis FB, et al. (2007) Thyroid hormone induces nuclear accumulation of monomeric integrin alpha V and formation of integrin-nucleoprotein complexes. Thyroid 17 (Suppl 1): S129.
24. Chaban VV, Lakhter AJ, Micevych P, (2004) A membrane estrogen receptor mediates intracellular calcium release in astrocytes. Endocrinology 145: 3788-3795.
25. Razandi M, Pedram A, Greene GL, Levin ER, (1999) Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 13: 307-319.
26. Lin HY, Tang HY, Keating T, Wu YH, Shih A, et al. (2008) Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 29: 62-69.
27. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB, (2000) Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 275: 38032-38039.
28. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV, (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101: 570-580.
29. Mori S, Wu CY, Yamaji S, Saegusa J, Shi B, et al. (2008) Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem 283: 18066-18075.
30. Somanath PR, Malinin NL, Byzova TV, (2009) Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12: 177-185.
31. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, et al. (2008) Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11: 183-190.
32. Shih A, Zhang S, Cao HJ, Tang HY, Davis FB, et al. (2004) Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-alpha are mediated by 3′,5′-cyclic adenosine 5′-monophosphate-dependent protein kinase II. Endocrinology 145: 1708-1717.
33. Lin HY, Zhang S, West BL, Tang HY, Passaretti T, et al. (2003) Identification of the putative MAP kinase docking site in the thyroid hormone receptor-beta1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 42: 7571-7579.
34. Bhargava M, Lei J, Ingbar DH, (2009) Nongenomic actions of L-thyroxine and 3,5,3′-triiodo-L-thyronine. Focus on "L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase". Am J Physiol Cell Physiol 296: C977-979.
35. Garcia-Silva S, Perez-Juste G, Aranda A, (2002) Cell cycle control by the thyroid hormone in neuroblastoma cells. Toxicology 181-182: 179-182.
36. Cao X, Kambe F, Moeller LC, Refetoff S, Seo H, (2005) Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 19: 102-112.
37. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA, (2008) Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11: 269-276.